Compare Novavax Inc (NVAX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Novavax Inc trades at $8.09 (market cap $1.30B), while State Street Technology Select Sector SPDR ETF trades at $180.4. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | XLK | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $11.19 | $198.21 |
52-Week Low | $6.22 | $127.49 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
XLK, the Technology Select Sector SPDR Fund, trades at $175.71 with a slight 0.07% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund has delivered strong year-to-date performance, up 33% as of July 2, 2026 (ETF Trends), but faces concentration risks in mega-cap tech holdings. Recent news highlights ongoing institutional interest in tech ETFs amid robust earnings expectations for the sector.
The outlook for XLK remains tied to technology sector strength, with Q2 earnings expected to show 23.3% growth for the S&P 500 (ETF Trends, July 13, 2026). Key risks include sector concentration and market volatility. Wall Street sentiment is positive due to strong fundamentals, but investors should monitor earnings results and Fed policy impacts on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
